Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Innovation Council · Finished

EDVance EDV2209 – a Paradigm shift in the treatment of stroke.

Coordinator
Edvince Aktiebolag, Sweden
Runs
1 January 2022 to 31 October 2024
Status
Finished
EU funding
€2.5m
Total cost
€4.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190148437

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite tremendous research efforts and a large number of clinical trials focused on developing treatments for stroke, the field's current state remains dismal. There are, at present, no efficient treatments nor promising drug candidates for this lethal and disabling condition. A different perspective with a new approach is therefore desperately needed. Edvince's drug discovery and development is born out of founder and Professor Lars Edvinsson's extensive, fundamental and pioneering research of cerebral circulation, receptor regulation, stroke and migraines.

Edvince is now ready to conduct the first clinical trial in 2022 with its innovative and disruptive lead drug EDV2209, an orphan drug for the treatment of brain ischemia associated with severe subarachnoid hemorrhage (SAH). The drug helps to keep the blood vessels in the brain open, allowing brain cells to receive oxygen and nutrients to prevent brain damage.

Topics

Who is involved

OrganisationCityCountryRole
Edvince AktiebolagLundSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI